Feed / ROIV

Roivant Sciences Ltd.

ROIV

Healthcare · 36.30 -1.4% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Roivant Sciences Ltd.'s move is being confirmed by its market group.

ROIV accounts for 14.0% of the group's measured movement across 6.0 effective names. raw member direction is mixed; 6 of 8 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#4 of 8 by movement share
Group movement share14.0%Absolute path energy—not portfolio weight
Relative path-1.69%aligned
Effective breadth6.0 / 8broad
Relative alignment6/8downside path · 1 counter-moving
Capital-flow agreement15%not yet clean
SEQUENCE READ

VKTX, SMMT moved materially before ROIV. ROIV crossed its material path threshold at 11:05 ET. IBRX, BBIO, ARWR followed.

EVIDENCE COVERAGE

5 of 8 members in Gene Editing Therapies are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 6 of 8 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as RLYB begins moving with the group.

Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.

Watch this read

Who this business touches

The relationships behind ROIV

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ALNYAlnylam Pharmaceuticals, Inc.supplierMay 29, 2025 ▾

“LNP platform : • Technology used in the first systemic RNA-LNP product to receive FDA-approval, Alnylam’s Onpattro (patisiran) for the treatment of polyneuropathy caused by hereditary ATTR amyloidosis.”

PFEPfizer, Inc.supplierMay 29, 2025 ▾

“In exchange for Pfizer’s inventory of these compounds, Priovant paid Pfizer $10.0 million.”

Depended on by

IMVTImmunovant, Inc.partnerMay 20, 2026 ▾

“108 Table of Contents Unallocated costs include: • personnel-related expenses, such as salaries, stock-based compensation and benefits, for research and development personnel; • costs allocated to us under our services agreements with Roivant Sciences Ltd.”

Filing peers

PTGXABBVIMNM

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 16 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ROIV is currently a Early Follower in the organic co-movement group Gene Editing Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.